Furthermore, patients with MSS CRC often present a highly immunosuppressive microenvironment, characterized by low tumor mutational burden (TMB), a scarcity of tumor‐infiltrating lymphocytes (TILs), and reduced PD‐L1 expression, which collectively hinder the effectiveness of PD‐1/PD‐L1 inhibitors [37, 44, 45]. This evidence concerns the gene CD274 and colorectal carcinoma.